| Rachel Brooke Maynard, AUD | |
|
272 Hospital Rd, Chillicothe, OH 45601-9031 | |
| (740) 779-7660 | |
| Not Available |
| Full Name | Rachel Brooke Maynard |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 12 Years |
| Location | 272 Hospital Rd, Chillicothe, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093057945 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | A.01806 (Ohio) | Primary |
| 237600000X | Audiologist-hearing Aid Fitter | A.01806 (Ohio) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Adena Medical Group Llc | 1153456579 | 342 |
| Mre Goc Inc | 6002155868 | 3 |
News Archive
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows.
Adult women are more than twice as likely to know how much they weighed in high school as they are to know their current cholesterol number, and only half of women have had their cholesterol tested in the past year, according to the results of a nationwide survey released today.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
› Verified 3 days ago
| Provider Name | Adena Medical Group Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1235468083 PECOS PAC ID: 1153456579 Enrollment ID: O20100323001007 |
News Archive
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows.
Adult women are more than twice as likely to know how much they weighed in high school as they are to know their current cholesterol number, and only half of women have had their cholesterol tested in the past year, according to the results of a nationwide survey released today.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
› Verified 3 days ago
| Provider Name | Mre Goc Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1699249474 PECOS PAC ID: 6002155868 Enrollment ID: O20190222001614 |
News Archive
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows.
Adult women are more than twice as likely to know how much they weighed in high school as they are to know their current cholesterol number, and only half of women have had their cholesterol tested in the past year, according to the results of a nationwide survey released today.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Brooke Maynard, AUD 272 Hospital Rd, Chillicothe, OH 45601-9031 Ph: () - | Rachel Brooke Maynard, AUD 272 Hospital Rd, Chillicothe, OH 45601-9031 Ph: (740) 779-7660 |
News Archive
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows.
Adult women are more than twice as likely to know how much they weighed in high school as they are to know their current cholesterol number, and only half of women have had their cholesterol tested in the past year, according to the results of a nationwide survey released today.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
› Verified 3 days ago
Dr. Shawn Stewart Cowell, AU.D, CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 17273 State Route 104, Audiology Department (126), Chillicothe, OH 45601 Phone: 740-773-1141 | |
Ms. Debra L. Morgan, M.A., CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 4439 State Route 159 Ste G70, Chillicothe, OH 45601 Phone: 740-779-4327 Fax: 740-779-4399 | |
Dr. Sabrina D. Greer, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 4439 State Route 159 Ste G70, Chillicothe, OH 45601 Phone: 740-779-4327 Fax: 740-779-4399 | |
Chelci Jo Gay, DR. Audiologist Medicare: Medicare Enrolled Practice Location: 2530 Western Ave Ste C, Chillicothe, OH 45601 Phone: 740-851-4727 | |
Dr. Erica Lynn Scudder, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 138 Marietta Rd, Chillicothe, OH 45601 Phone: 740-775-4327 | |
Ashtyn Rife, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 4439 State Route 159 Ste G70, Chillicothe, OH 45601 Phone: 740-779-4327 |